Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Investor Presentation (October 2024)
33 slides from Sonoma Pharmaceuticals's investor presentation, Oct 22, 2024
Slide 1: Sonoma Pharmaceuticals, Inc. Investor Presentation October 2024
Sonoma Pharmaceuticals, Inc. Investor Presentation October 2024
Slide 2: Legal Disclaimers
Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness
Slide 3: About Sonoma
About Sonoma Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non - toxic disinfectan
Slide 4: Hypochlorous Acid Industry Leader
Hypochlorous Acid Industry Leader 21 U.S. FDA clearances as 510(k) medical devices, CE marks for over 39 products, and extensive worldwide regulatory clearances Utilized on millions of patients worldwide without a single report of serious adverse effect Focused on billion - dollar markets in Rx and
Slide 5: Sonoma's Microcyn Technology
Sonoma’s Microcyn ® Technology Patented, Stabilized Triple - Action Topical Technology • HOCl kills microbes including bacteria, fungi and viruses while assisting healing • Relieves pain and itch • Improves wound care by cleaning and moistening the wound and peri - wound area • Safely manage skin ab
Slide 6: Sonoma's Microcyn Technology: Safety and Industry Leader
Sonoma’s Microcyn ® Technology Unparalleled Safety • No drug - to - drug interaction or contraindications • Millions of patients treated worldwide without a single report of serious adverse effect • 30+ human clinical trials with over 1,500 patients • Products contain all - natural hypochlorous acid
Slide 7: Research articles and case and clinical studies
Over 100 research articles and case and clinical studies showcasing both the efficacy and safety of our Microcyn ® technology bs/pii/S0099239917 y of Barcelona, 11/27 evention, see https:// management in derm ized - HOCL - consens apharma.com/wp - con 310439 /2020 sonomapharma.com/wp - atologic and
Slide 8: Wide Range of Applications
Wide Range of Applications Wound Care Dermatology Eye Care Oral and Dental Care Animal Health Care Surface Disinfectants Podiatry Nasal Care 8
Slide 9: Our Wound Care Business is Growing in the U.S. and Internationally
Our Wound Care Business is Growing in the U.S. and Internationally • Celebrating 20 years of selling wound care • In August 2024, we added Medline Industries, LP as a U.S. distributor for our wound care products – Medline is one of the largest medical supply distributors in the United States • In Oc
Slide 10: Industry-Leading Safe and Effective Dermatology Products
Industry - Leading Safe and Effective Dermatology Products • Products to relieve symptoms of atopic dermatitis, reduce scarring, and for daily skin care • Line of office dispense products targeting growing med spa market • Eczema seal of approval • All natural ingredients • No harmful chemicals • OT
Slide 11: Expanded Eye Care Product Line
Expanded Eye Care Product Line • Sonoma has the strongest FDA indications for eye care in the HOCl industry • OTC and prescription eye care sold into multiples channels • Strong CE Mark for eye care sales in the EU • Animal health eye care sold in major chains including PetSmart and Tractor Supply 1
Slide 12: Safety in Dermatology Products
Safety in Dermatology Products ers Recently, there has been concern by dermatologists that popular dermatology products can form benzene , a known carcinogen. • Citizen petition by Valisure, LLC, an independent testing laboratory for pharmaceuticals, requested an FDA recall of certain over - the - c
Slide 13: Safety in Eye Care
Safety in Eye Care The FDA has issued safety warnings for certain eye products after finding unsanitary conditions in the manufacturing facilities and positive bacterial test results from environmental sampling. • The warnings in October 2023 applied to eye drops by brands such as CVS , Rite Aid , T
Slide 14: Robust U.S. and International Distribution Network
Robust U.S. and International Distribution Network OVER 40 GLOBAL PARTNERS AND GROWING We continue to: • Expand our presence in new markets by replicating what works in existing markets • Add new distribution partners and grow existing relationships • Co - develop innovative new products with partne
Slide 15: Cutting Edge Manufacturing
• 57,153 square foot state - of - the - art facility • ISO 9001, ISO 13485 and cGMP certified • MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and numerous other national listings and approvals • Shipping to over 55 countries, with multiple methods for shipments • Highly trained staff of 162 employees • Add
Slide 16: Manufacturing Facility
Manufacturing Facility 16
Slide 17: Growth Strategy
Continue to introduce new high margin products Manufacturing capabilities can support significant future growth, leading to improved margins overall • Launch new applications of Sonoma’s Microcyn® technology for consumer - focused products, including in the dermatology and aesthetic space Growth Str
Slide 18: New Market Opportunities
New Market Opportunities Sonoma is expanding its partnerships and product offerings in the eye care, all - natural skin care, medical spa and animal health care industries. • The global eye care market size was estimated at USD $70.78 billion in 2023 and is projected to grow at a compound annual gro
Slide 19: Introduction of new products using our Microcyn technology
Introduction of new products using our Microcyn ® technology • In September 2024, we announced the consumer - friendly redesign of Ocucyn® Eyelid & Eyelash Cleanser . • In April 2024 , we announced expansion of our Microcyn® Negative Pressure Wound Therapy Solution product line, now available in 250
Slide 20: Expanding commercialization opportunities by investing in R&D
Expanding commercialization opportunities by investing in R&D • In September 2024, we received a new 510(k) clearance from the FDA, including specific over - the - counter indications for the face, eyelid and eyelashes and a smaller product size. • In March 2023 , we announced new EPA claims for Nan
Slide 21: Continuously expanding our distributor network
Continuously expanding our distributor network • In August 2024, we announced a new distribution agreement with Medline Industries, LP for the marketing and distribution of our wound care products in the United States . • In October 2024, we expanded our agreement with Medline for marketing and dist
Slide 22: Management
Management Amy Trombly CEO Amy Trombly 22 is our Chief Executive Officer and also serves on our Board of She counseled public for over two decades in Directors. companies corporate and securities law and mergers and acquisitions, including as the owner and manager of Trombly Business Law, PC . In he
Slide 23: Key Financial Metrics
Key Financial Metrics 23 Year ended March 31, 2024 - » Gross profit margin improved 3% in FY 2024 compared to FY 2023 » Net loss improved 6% in FY 2024 compared to FY 2023 Three months ended June 30, 2024 - » European revenues increased 20% compared to same period in 2023 » Gross margin of 39% compa
Slide 24: APPENDIX: Product Portfolio
APPENDIX: Product Portfolio
Slide 25: Diverse Product Portfolio
Diverse Product Portfolio United States Lumacyn Clarifying Mist Microcyn Rx Skin & Wound Care Regenacyn Scar Gel Epicyn Facial Cleanser Nanocyn Hospital Grade Disinfectant Levicyn Dermal Spray and Gel Celacyn Scar Management Gel Rejuvacyn Skin Repair Reliefacyn Itch, Burn, Rash & Pain Care Microcyn
Slide 26: U.S. Dermatology
U.S. Dermatology • Office dispense products exclusively for skin care professionals • Generates highest margins for Sonoma • Focused marketing to med spas and dermatology offices, which can resell products to their clients for a substantial margin 26
Slide 27: U.S. Animal Health Care
U.S. Animal Health Care MicrocynAH ® family of advanced animal healthcare products, safe to use on pets and livestock, and perfect for hot spots, pink eye, scratches, skin rashes and ulcers, cuts, burns, post - surgical sites, irritated skin and lacerations. • Sold in national pet - store retail cha
Slide 28: EU Products
Epicyn ® Dermatology Gramaderm ® Dermatology Pediacyn ® Dermatology Mucoclyns ® Decontamination solution Microdacyn60 ® Oral Care Blocked nose or sinuses Sinudox ® Nasal care Blepharitis treatment Ocudox ® Eye lid solution Exposure to germs and pathogens Mouth and throat infections Keloid or hypertr
Slide 29: Direct-to-consumer products
Direct - to - consumer products available through Shopify, Amazon and Amazon EU U.S. Products EU Products 29
Slide 30: Middle East products
& Middle East Microdacyn Microsafe Wound Care ace Cool, Anti-Microbial, Baby Cool, Foot Coo, Lay Cool Microsafe Disinfectant & Sanitizer
Slide 31: Asia products
Singapore, Malaysia, Thailand, Indonesia Wound Care South Korea BioDerm Biodacyn60 Wound Care Hong Kong Microdacyn60 Oral Care China Microcyn The Philippines Microdacyn MicrocynAH ® Asia 31
Slide 32: Latin America and Australia & New Zealand products
Gramacyn Kit for Acne Skin Latin America Epicyn Treat Scars Right from the Start Australia & New Zealand 32
Slide 33: Thank You
THANK YOU Sonoma Pharmaceuticals Inc. 5445 Conestoga Court, Suite 150 Boulder, CO 80301 United States of America Phone: 1 - (800) 759.9305 Email: busdev@sonomapharma.com Website: www.sonomapharma.com NASDAQ: SNOA
Sonoma Pharmaceuticals — Investor Presentation (October 2024) on 6ix